| 7.16 0.15 (2.14%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.39  |
1-year : | 16.44 |
| Resists | First : | 10.61 |
Second : | 14.07 |
| Pivot price | 6.56 |
|||
| Supports | First : | 5 | Second : | 4.15 |
| MAs | MA(5) : | 6.75  |
MA(20) : | 7.29 |
| MA(100) : | 8.12 |
MA(250) : | 6.81 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 53.2 |
D(3) : | 39.8 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 17.39 | Low : | 2.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KZIA ] has closed below upper band by 24.7%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.42 - 7.45 | 7.45 - 7.48 |
| Low: | 6.83 - 6.86 | 6.86 - 6.89 |
| Close: | 7.11 - 7.16 | 7.16 - 7.22 |
Thu, 08 Jan 2026
Breast cancer drug update expected this month as Kazia heads to JP Morgan - Stock Titan
Mon, 22 Dec 2025
Kazia Therapeutics regains full Nasdaq listing compliance - Investing.com
Mon, 22 Dec 2025
Kazia Therapeutics Regains Full Nasdaq Listing Compliance - Yahoo Finance
Fri, 19 Dec 2025
Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance - TipRanks
Tue, 02 Dec 2025
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - Yahoo Finance
Sun, 23 Nov 2025
Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 11 (M) |
| Shares Float | 905 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -12.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.43 |
| Profit Margin | 0 % |
| Operating Margin | -268.4 % |
| Return on Assets (ttm) | -64.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -27.3 % |
| Gross Profit (p.s.) | 0.16 |
| Sales Per Share | 0.16 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | 0 |
| Price to Book value | -2.1 |
| Price to Sales | 44.36 |
| Price to Cash Flow | -6.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|